Last updated July 13, 2026
Key finding
FLO23011 significantly improved post-hypoglycaemia time in range (82.5% vs. 77.0%, p = 0.019)
FLO23011, a novel glucose and beta-hydroxybutyrate combination, in adults with type 1 diabetes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
FLO23011, a novel glucose and beta-hydroxybutyrate combination, in adults with type 1 diabetes.
This study evaluated FLO23011, a novel glucose and beta-hydroxybutyrate combination, in adults with type 1 diabetes.
Limitations were not clearly described in the extracted text.
Published in
Publication details and source links for this paper.
D. R, V. S, S. R, G. M, R. L, F. S. FLO23011: A Novel Multi-Substrate Energy Formulation for Hypoglycaemia Management. Diabetes, Obesity & Metabolism. 2025;28(5):3590-3597. doi:10.1111/dom.70323
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to FLO23011 and Hypoglycaemia confidence measured by the Hypoglycemia Confidence Scale, Overall patient experience across 14 domains, Percentage reduction in recurrent hypoglycaemia episodes, and 1 more.
This study contributes evidence to
Primary intervention
FLO23011
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
4
Evidence pairs
171
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Core evidence
The primary outcomes reported in this study.
FLO23011 → Hypoglycaemia confidence measured by the Hypoglycemia Confidence Scale
FLO23011 → Hypoglycaemia confidence measured by the Hypoglycemia Confidence Scale
FLO23011 → Overall patient experience across 14 domains
FLO23011 → Overall patient experience across 14 domains
FLO23011 → Percentage reduction in recurrent hypoglycaemia episodes
FLO23011 → Percentage reduction in recurrent hypoglycaemia episodes
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on FLO23011 and Hypoglycaemia confidence measured by the Hypoglycemia Confidence Scale, FLO23011 and Overall patient experience across 14 domains.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies on FLO23011
Contributes to FLO23011 evidence base.
All studies measuring Hypoglycaemia confidence measured by the Hypoglycemia Confidence Scale
Measures Hypoglycaemia confidence measured by the Hypoglycemia Confidence Scale as a key outcome.
All studies measuring Overall patient experience across 14 domains
Measures Overall patient experience across 14 domains as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
FLO23011 appears to improve Overall patient experience across 14 domains.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Overall patient experience across 14 domains
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
FLO23011 appears to improve Percentage reduction in recurrent hypoglycaemia episodes.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage reduction in recurrent hypoglycaemia episodes
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
FLO23011 appears to improve Time in range.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time in range
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of FLO23011 for Hypoglycaemia confidence measured by the Hypoglycemia Confidence Scale.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Hypoglycaemia confidence measured by the Hypoglycemia Confidence Scale
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
